Published in J Hepatol on November 13, 2006
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab (2009) 2.05
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A (2013) 1.75
Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology (2009) 1.72
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology (2010) 1.59
Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog (2007) 1.56
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Hepatitis C virus host cell entry. Curr Opin Virol (2012) 1.41
Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol (2010) 1.39
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol (2012) 1.28
Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab (2011) 1.27
Multifaceted roles for lipids in viral infection. Trends Microbiol (2011) 1.22
Lipids and HCV. Semin Immunopathol (2012) 1.19
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog (2010) 1.16
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol (2009) 1.14
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Hepatitis C virus utilizes lipid droplet for production of infectious virus. Proc Jpn Acad Ser B Phys Biol Sci (2009) 1.09
Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One (2008) 1.09
Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog (2013) 1.08
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol (2010) 1.07
Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology (2011) 1.06
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem (2012) 1.03
Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein. J Biol Chem (2011) 1.02
Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J (2009) 1.01
Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol (2012) 0.97
Lipid metabolism and HCV infection. Viruses (2010) 0.96
Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol (2014) 0.96
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology (2010) 0.94
Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. PLoS Pathog (2014) 0.93
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology (2013) 0.93
Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) (2014) 0.91
Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem (2012) 0.91
The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population. HIV Med (2009) 0.91
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry. J Biol Chem (2011) 0.91
Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol (2013) 0.90
Murine models of hepatitis C: what can we look forward to? Antiviral Res (2014) 0.90
Modular bioreactor for primary human hepatocyte culture: medium flow stimulates expression and activity of detoxification genes. Biotechnol J (2011) 0.89
Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses (2012) 0.88
Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci Rep (2014) 0.87
Recent advances in hepatitis C virus cell entry. Viruses (2010) 0.87
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) (2009) 0.86
Targeting HCV entry for development of therapeutics. Viruses (2010) 0.86
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol (2015) 0.85
How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol (2014) 0.85
Hepatitis C virus: a new class of virus associated with particles derived from very low-density lipoproteins. Arterioscler Thromb Vasc Biol (2012) 0.85
Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. J Virol (2013) 0.85
Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS One (2011) 0.84
Entry inhibitors: New advances in HCV treatment. Emerg Microbes Infect (2016) 0.84
HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection. AIDS (2014) 0.84
Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). Viruses (2012) 0.83
Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. World J Gastroenterol (2009) 0.83
Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions. J Biol Chem (2014) 0.83
Binding of liver derived, low density hepatitis C virus to human hepatoma cells. J Med Virol (2008) 0.83
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the Northeast of Brazil. Nutr J (2011) 0.82
Visualizing hepatitis C virus infection in humanized mice. J Immunol Methods (2014) 0.82
Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol (2015) 0.82
Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins. J Biol Chem (2010) 0.81
MTP -493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients. Braz J Med Biol Res (2011) 0.80
Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain. J Biol Chem (2009) 0.80
In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. J Hepatol (2006) 0.79
Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. Virol J (2011) 0.79
Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J Viral Hepat (2011) 0.79
Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses (2012) 0.78
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. World J Gastroenterol (2011) 0.78
Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. Genes Immun (2013) 0.78
Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies? Cancer Lett (2013) 0.78
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One (2016) 0.78
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
The effect of antiviral therapy on serum cholesterol levels in chronic hepatitis C. Gut Liver (2011) 0.77
Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. Scientifica (Cairo) (2012) 0.77
Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments. Int J Hepatol (2012) 0.77
Entry of hepatitis C virus into the cell: a therapeutic target. World J Gastroenterol (2012) 0.76
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol (2014) 0.76
Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol (2016) 0.76
New hepatitis C virus drug discovery strategies and model systems. Expert Opin Drug Discov (2012) 0.76
Interferon Control of the Sterol Metabolic Network: Bidirectional Molecular Circuitry-Mediating Host Protection. Front Immunol (2016) 0.75
A Novel Human Radixin Peptide Inhibits Hepatitis C Virus Infection at the Level of Cell Entry. Int J Pept Res Ther (2014) 0.75
Roles of lipoprotein receptors in the entry of hepatitis C virus. World J Hepatol (2015) 0.75
Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2. Gastroenterol Res Pract (2012) 0.75
Hepatitis C virus heterogeneity: lipoprotein and immunoglobulin binding and clinical status. J Clin Exp Hepatol (2013) 0.75
Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response. World J Gastroenterol (2015) 0.75
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. Eur J Clin Microbiol Infect Dis (2013) 0.75
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol (2011) 4.77
Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med (2006) 4.46
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum. J Biol Chem (2003) 2.96
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev (2008) 2.92
Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery (2005) 2.50
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature (2003) 2.14
Functional role and prognostic significance of CD157 in ovarian carcinoma. J Natl Cancer Inst (2010) 2.08
Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity (2005) 2.08
Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol (2005) 2.06
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol (2010) 2.02
Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol (2011) 2.02
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood (2003) 1.99
Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest (2005) 1.96
The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol (2008) 1.76
CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood (2004) 1.63
Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem (2002) 1.61
USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS One (2011) 1.60
apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53. Cell Cycle (2010) 1.59
TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci (2006) 1.55
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut (2010) 1.55
Development of hepatitis C virus genotype 3a cell culture system. Hepatology (2014) 1.53
Treatment with 9-cis β-carotene-rich powder in patients with retinitis pigmentosa: a randomized crossover trial. JAMA Ophthalmol (2013) 1.53
An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol (2012) 1.51
Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol Ther (2008) 1.49
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol (2011) 1.47
Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol (2003) 1.47
Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie. Ann Surg Oncol (2015) 1.46
Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatol (2010) 1.45
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab (2002) 1.45
Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. Isr Med Assoc J (2002) 1.43
Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res (2002) 1.40
Identification of a novel determinant for membrane association in hepatitis C virus nonstructural protein 4B. J Virol (2009) 1.37
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood (2007) 1.35
Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol (2002) 1.35
Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci Res (2010) 1.35
Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis (2006) 1.34
CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res (2009) 1.34
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm (2007) 1.32
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol (2011) 1.29
CD molecules 2005: human cell differentiation molecules. Blood (2005) 1.27
Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology (2012) 1.25
Label-free detection of bacteria by electrochemical impedance spectroscopy: comparison to surface plasmon resonance. Anal Chem (2007) 1.23
Human hepatocyte culture. Methods Mol Biol (2006) 1.23
CD molecules 2006--human cell differentiation molecules. J Immunol Methods (2006) 1.23
Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem (2001) 1.23
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica (2013) 1.21
CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood (2005) 1.20
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care (2009) 1.19
Accelerated lipid absorption in mice overexpressing intestinal SR-BI. J Biol Chem (2006) 1.19
Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood (2002) 1.19
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology (2009) 1.17
Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology (2004) 1.17
Ecto-F1Fo ATP synthase/F1 ATPase: metabolic and immunological functions. Curr Opin Lipidol (2006) 1.15
Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion (2002) 1.15
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology (2013) 1.14
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res (2011) 1.13
Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol (2008) 1.12
CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol (2004) 1.11
CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood (2007) 1.11
Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation (2010) 1.11
The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol (2003) 1.10
Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1α. Biochem Biophys Res Commun (2011) 1.10
Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol Endocrinol (2003) 1.10
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem (2013) 1.09
CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol Med (2007) 1.08
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology (2013) 1.07
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res (2003) 1.07
Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat (2002) 1.07
Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn. Exp Cell Res (2010) 1.06
A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology (2009) 1.06
Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf (2005) 1.05
Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol (2012) 1.05
CD38 signaling in T cells is initiated within a subset of membrane rafts containing Lck and the CD3-zeta subunit of the T cell antigen receptor. J Biol Chem (2003) 1.05
The circadian clock components CRY1 and CRY2 are necessary to sustain sex dimorphism in mouse liver metabolism. J Biol Chem (2009) 1.04
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther (2013) 1.04
RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. Cell Signal (2008) 1.04